ARIPIPRAZOLE LAUROXIL: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533	NDA	Alkermes, Inc.	65757-401-03	1 SYRINGE in 1 CARTON (65757-401-03) / 1.6 mL in 1 SYRINGE	2015-10-05
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533	NDA	Alkermes, Inc.	65757-401-04	1 SYRINGE in 1 CARTON (65757-401-04) / 1.6 mL in 1 SYRINGE	2015-10-05
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533	NDA	Alkermes, Inc.	65757-402-03	1 SYRINGE in 1 CARTON (65757-402-03) / 2.4 mL in 1 SYRINGE	2015-10-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 27, 2025

Introduction

Aripiprazole Lauroxil is a long-acting injectable antipsychotic indicated primarily for the treatment of schizophrenia in adults. As a prodrug of aripiprazole, it offers extended-release pharmacokinetics, reducing dosing frequency and enhancing medication adherence. Its strategic positioning within the mental health therapeutics market hinges significantly on the reliable sourcing of high-quality raw materials, active pharmaceutical ingredients (APIs), and finished formulations. This article delineates the leading suppliers involved in the supply chain of aripiprazole lauroxil, analyzing their roles, geographic distribution, regulatory compliance, and market influence to inform stakeholders seeking partnership or procurement options.

Manufacturers of Aripiprazole Lauroxil Active Pharmaceutical Ingredient (API)

AbbVie Inc. – Originator and Key API Supplier

AbbVie, a global biopharmaceutical leader, holds the original patent and manufacturing rights for aripiprazole lauroxil. The company developed this compound as part of its neuropsychopharmacology portfolio. AbbVie's manufacturing facilities in the United States produce bulk API, emphasizing stringent quality control to meet FDA standards. Their integrated supply chain ensures consistency in API quality, which is critical for regulators and quality-conscious pharmaceutical companies seeking to produce authorized generic versions or branded formulations.

Key attributes:

Proprietary API production processes
Regulatory compliance aligned with FDA and EMA standards
Capacity for large-scale production

Implication:
Partnering directly with AbbVie ensures priority access to high-purity APIs, albeit often at premium costs due to the proprietary nature and intellectual property protections.

Contract Manufacturing Organizations (CMOs) of API Production

Following patent expiration or during development stages, several CMOs have emerged as alternative API suppliers:

Haupt Pharma: Based in Switzerland, Haupt Pharma offers synthesis and manufacturing of APIs, including derivatives like aripiprazole lauroxil, with a focus on quality adherence and regulatory approvals aligned with EU standards.
Mundipharma: While primarily a pharmaceutical company, Mundipharma collaborates with CMOs for API production, particularly for off-patent or generic versions.
Biocon and Dr. Reddy’s Laboratories: These Indian-based pharmaceutical innovators have developed capabilities for generic APIs, including complex molecules such as aripiprazole derivatives. Their process involves licensed manufacturing agreements with patent holders initially, then transitioning to independent production post-expiry.

Implication:
The proliferation of CMOs expands supply options, often at reduced costs, but necessitates rigorous due diligence regarding validation, quality assurance, and regulatory compliance.

Suppliers of Finished Pharmaceutical Products (FPP)

AbbVie – Original Manufacturer

AbbVie remains the sole supplier of the brand-name formulations of aripiprazole lauroxil. Their formulations are distributed globally through direct sales, with a strong presence in North America and Europe. Their extensive distribution network ensures consistent market availability but limits supply flexibility for third-party manufacturers.

Generic Manufacturers

Following patent expiration, several generic pharmaceutical companies have entered the market with approved formulations:

Alvogen: An international generic producer with FDA ANDA approvals for aripiprazole lauroxil. Their formulations meet bioequivalence standards, and they supply in North America and Europe.
Sandoz (Novartis): Sandoz markets generic versions globally, emphasizing regulatory adherence and cost competitiveness.
Lupin Ltd.: An Indian pharmaceutical giant with manufacturing and export capabilities for generic long-acting injectables, including aripiprazole lauroxil.

Implication:
The presence of multiple generic suppliers fosters competitive pricing but requires careful verification of bioequivalence and quality standards, especially for injectable formulations.

Distribution and Supply Chain Dynamics

The supply chain for aripiprazole lauroxil spans from API manufacturing to finished product distribution. Key factors influencing supply include regulatory approvals, manufacturing capacity, patent status, and regional distribution agreements.

Regulatory Environment:
The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) enforce strict GMP standards, impacting both API and finished product suppliers' operational compliance. Variability in regulatory recognition influences market access and export potential.
Patent Landscape:
Original patents held by AbbVie constrained market entry until patent expiry prompted generic proliferation. Patent cliffs catalyze the emergence of alternative suppliers, expanding options but necessitating vigilance regarding patent rights.
Manufacturing Capacity and Lead Times:
Manufacturers increasingly invest in expanding capacity to meet global demand, especially amid growing recognition of long-acting injectables. Lead times for scaled production can influence market availability and strategic planning.

Regional Considerations and Market Access

Suppliers are geographically dispersed, with prominent markets including North America, Europe, and Asia-Pacific:

North America:
Predominantly supplied by AbbVie and US-based generic manufacturers. Stringent regulatory standards ensure high product quality but can pose hurdles for new entrants.
Europe:
Manufacturers like Haupt Pharma and Sandoz dominate, with regulatory pathways adhering to EMA standards. Distribution channels facilitate broad access across member states.
Asia-Pacific:
Countries such as India and China have burgeoning generic manufacturing sectors, producing both active ingredients and finished products for domestic and export markets. Local regulatory frameworks are evolving to align with international standards.

Quality Assurance and Regulatory Compliance

Suppliers in this niche pharmaceutical segment must adhere to comprehensive quality assurance protocols, including validation of manufacturing processes, stability testing, and bioequivalence studies. Regulatory approvals are prerequisites for market entry and include documentation like Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs).

Conclusion

The landscape of suppliers for aripiprazole lauroxil is characterized by a mix of innovative originators like AbbVie and a broad array of generic manufacturers especially post-patent expiry. Ensuring supply security requires due diligence on regulatory status, manufacturing capacity, quality standards, and regional distribution networks. The increasing landscape of CMOs offers opportunities for cost-effective sourcing but demands rigorous validation processes.

Key Takeaways

Market leaders like AbbVie dominate primary supply chains for aripiprazole lauroxil, emphasizing quality and regulatory compliance.
Post-patent expiry, multiple generic manufacturers, primarily from India and Europe, have entered the field, increasing supply diversity and competitive pricing.
Regulatory approval and bioequivalence are critical considerations when selecting suppliers, particularly for generic injectable formulations.
Geographical considerations influence supply reliability, cost, and market access, with diverse manufacturing hubs in North America, Europe, and Asia.
Supply chain stability depends on manufacturing capacity, patent status, and regional regulatory climates, highlighting the importance of strategic supplier relationships.

FAQs

1. Who are the primary suppliers of aripiprazole lauroxil API?
Original API production is primarily managed by AbbVie, with contract manufacturing organizations such as Haupt Pharma and Indian generics like Dr. Reddy’s Laboratories also providing alternative sources post-patent expiration.

2. Are there global supply shortages of aripiprazole lauroxil?
Supply stability varies geographically; high demand, manufacturing capacity constraints, or regulatory delays can cause shortages. Currently, multiple global suppliers mitigate significant shortages, but regional disparities may exist.

3. How do regulatory standards influence supplier choice?
Suppliers compliant with FDA, EMA, and other regional regulatory standards ensure product quality and facilitate market access, making regulatory adherence a key criterion for procurement decisions.

4. What role do CMOs play in the supply chain?
CMOs expand production capacity, reduce costs, and support pharmaceutical companies during scale-up or developmental phases. Rigorous validation and regulatory approval are essential for their involvement.

5. How does patent status affect supplier options?
Patent expiry opens the market to generic manufacturers, increasing supplier options and competition, which can lead to price reductions and supply diversification.

References

[1] U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
[2] European Medicines Agency. EPAR for Aripiprazole Lauroxil.
[3] AbbVie Inc. Corporate Website. Product Pipeline and Manufacturing Capabilities.
[4] Clinical Pharmacology. Aripiprazole Lauroxil: Pharmacokinetics and Supply Chain Overview.
[5] GlobalData. Market Intelligence Report on Long-Acting Injectables.

Suppliers and packagers for generic pharmaceutical drug: ARIPIPRAZOLE LAUROXIL